Immunic reports positive top-line data from phase 2 emphasis trial of imu-838

Immunic, inc. reports positive top-line data from phase 2 emphasis trial of imu-838 in patients with relapsing-remitting multiple sclerosis.q2 loss per share $0.90.immunic- study meets primary, key secondary endpoints with high statistical significance.cash and cash equivalents, as of june 30, 2020, were $48.6 million.
IMUX Ratings Summary
IMUX Quant Ranking